| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- LDN-214117
-
- $33.00
-
2026-07-27
- CAS:1627503-67-6
- Purity: 99.85%
- Supply Ability: 10g
|
| | LDN-214117 Basic information |
| Product Name: | LDN-214117 | | Synonyms: | 1-[4-[6-Methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl]piperazine;LDN-214117;LDN214117;CS-1539;LDN-214117;1-(4-(6-methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine;Piperazine, 1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl]-;LDN-214117 USP/EP/BP;LDN214117,LDN-214117,ALK2,BMP4,BMP2,Transforming growth factor beta receptors,LDN 214117,BMP6,TGF-β Receptor,diffuse intrinsic pontine glioma(DIPG),oral,ALK3,fibrodysplasia ossificans progressiva (FOP),ALK5,type I receptor kinases,ALK1,bone morphogenetic proteins (BMPs) | | CAS: | 1627503-67-6 | | MF: | C25H29N3O3 | | MW: | 419.52 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1627503-67-6.mol |  |
| | LDN-214117 Chemical Properties |
| Boiling point | 567.9±50.0 °C(Predicted) | | density | 1.134±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMF:30.0(Max Conc. mg/mL);71.51(Max Conc. mM)
DMF:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.19(Max Conc. mM)
DMSO:42.67(Max Conc. mg/mL);101.7(Max Conc. mM)
Ethanol:54.0(Max Conc. mg/mL);128.72(Max Conc. mM) | | pka | 8.86±0.10(Predicted) | | form | Powder | | color | Light yellow to yellow | | InChI | 1S/C25H29N3O3/c1-17-22(19-14-23(29-2)25(31-4)24(15-19)30-3)13-20(16-27-17)18-5-7-21(8-6-18)28-11-9-26-10-12-28/h5-8,13-16,26H,9-12H2,1-4H3 | | InChIKey | BHUXVRVMMYAXKN-UHFFFAOYSA-N | | SMILES | CC(C(C1=CC(OC)=C(OC)C(OC)=C1)=C2)=NC=C2C(C=C3)=CC=C3N4CCNCC4 |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | WGK Germany | WGK 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | LDN-214117 Usage And Synthesis |
| Uses | LDN 214117 is a highly selective ALK2 inhibitor. | | Biological Activity | LDN-214117 is a selective inhibitor of the bone morphogenetic protein (BMP) type I receptor kinases with high selectivity for BMP versus TGF-β signaling, and low cytotoxicity. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM, followed by TNIK, RIPK2, and ABL1. LDN-214117 has a cell-based IC50 for BMP6 of approximately 100 nM and 164-fold selectivity for BMP6 versus TGF-β1. Fibrodysplasia ossificans progressiva (FOP) is a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. LDN-214117 had nearly identical binding affinity for wild-type ALK2 and each of the FOP-causing mutants tested. | | in vivo | LDN-214117 (p.o., 25 mg/kg, daily, for 14 days) has well-tolerated in mice[3].
| Animal Model: | NOD.SCID mice[3] | | Dosage: | 25 mg/kg | | Administration: | p.o., daily, for 14 days | | Result: | Showed good-tolerated in mice. |
|
| | LDN-214117 Preparation Products And Raw materials |
|